EGFR and non-small cell lung carcinoma: One meta-analysis including individual data from 1231 patients enrolled in 6 RTCs of EGFR-TKI vs. chemotherapy in EGFR-mutant NSCLC patients did not find any differences in pooled OS-HRs in women (HR = 1.02; 95% CI = 0.86–1.21) and men (HR = 0.98; 95% CI = 0.76–1.27).